Overview

Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The aim of this study is assess the safety and efficacy of the treatment regimen of basiliximab ,cyclosporine microemulsion, MMF, and prednisone combined compared to cyclosporine microemulsion, MMF and prednisone in the time to first biopsy proven acute rejection episode or treatment failure during the first 6 months post-transplantation in pediatric renal allograft recipients.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Antibodies, Monoclonal
Basiliximab
Cyclosporine
Cyclosporins
Mycophenolate mofetil
Mycophenolic Acid
Prednisone